Patient P-01570
Synthetic patientNBL-101 · Day 116 · 65–74 · M · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Unstable
Discontinuation risk
72%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 31 NP-02 recommended — Dietary Support Protocol NP-02
- Day 32 Patient accepted — Started NP-02 in the companion
- Day 42 No meaningful change — Dietary Support Protocol NP-02
- Day 48 SC-12 recommended — Supportive Compound SC-12
- Day 49 Patient accepted — Started SC-12 in the companion
- Day 53 GI-04 recommended — GI Support Protocol GI-04
- Day 54 Patient accepted — Started GI-04 in the companion
- Day 55 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 55 GI symptom burden −25% vs expected — Supportive Compound SC-12
- Day 61 Tolerance state changed — Unstable → Improving
- Day 62 No meaningful change — GI Support Protocol GI-04
What changed?
Trajectory began diverging from predicted response on Day 55.
Primary contributors, last 14 days
- Nutritional resilience-8
- Treatment adherence-8
- GI instability+6
- Inflammatory activity+4
- Toxicity+2
What helped?
- Dietary Support Protocol NP-02Day 31Result: no meaningful change
- Supportive Compound SC-12Day 48Result: symptom burden −25%
- GI Support Protocol GI-04Day 53Result: no meaningful change
LIFE OS recommendation
Monitoring Escalation ME-01
88%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 100% showed improvement
- median effect visible after 3 days
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion50.3/100
stable · +0.7 vs previous 14 d
Toxicity
Blood44.4/100
worsening · +1.9 vs previous 14 d
Sleep quality
Wearable27.6/100
worsening · -4.0 vs previous 14 d
Energy level
Daily log3.6/10
improving · +0.2 vs previous 14 d
Stress level
Daily log6/10
stable · -0.0 vs previous 14 d
Steps
Wearable1,981
worsening · -272 vs previous 14 d
Adherence
Companion50.3 %
worsening · -5.5 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 33 from the failing basin, 54 from restoration.
Would help
Would not help
- GI-04 GI Support Protocolalready tried, no meaningful change
- NP-02 Dietary Support Protocolalready tried, no meaningful change
- Keep fat lowGI +3.1 next day on high-intake days · n 19
- Keep histamine lowGI +2.9 next day on high-intake days · n 19
- Keep simple carbs lowGI +2.4 next day on high-intake days · n 19
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+3.1detractor · 95%
- Histamine load+2.9detractor · 95%
- Simple carbohydrates+2.4detractor · 77%
- Alcohol-1.2no signal · 41%
- Spicy / capsaicin+1no signal · 33%
- Insoluble fibre+0.4no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓90
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 50 and rising
- WearableSleep 5.7 h, below personal baseline
- Autonomic recovery ↓65
- WearableResting HR 74 bpm
- Wearable1,981 steps/day
- WearableShort sleep window
- Drug metabolism and exposure ↑60
- DNACYP2D6 poor metabolizer → higher exposure
- BloodToxicity index 44
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 23/100
- Daily logFibre intake low in recent food logs
- Inflammatory signalling ↑45
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 51
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Poor metabolizerHigher exposure at standard dose
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 1.9 · butyrate capacity 23/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 43 ms
- Sleep
- 5.5 h
- Steps
- 2,752
- Resting HR
- 74 bpm
Daily log: GI score 50, nutritional resilience 38, adherence 50.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- A 15-minute walk after lunch
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01377 | 23% | S11 | AD-05 | no change | 42 |
| P-01483 | 23% | S14 | AD-05 | no change | 35 |
| P-01371 | 33% | S06 | CR-01 | improved | 63 |
| P-01708 | 33% | S07 | CR-01 | improved | 59 |
| P-01696 | 32% | S20 | CR-01 | improved | 59 |
| P-01388 | 30% | S17 | CR-01 | improved | 59 |
| P-01835 | 30% | S17 | CR-01 | improved | 56 |
| P-01442 | 29% | S13 | CR-01 | improved | 61 |
| P-01877 | 28% | S01 | CR-01 | improved | 67 |
| P-01430 | 24% | S05 | CR-01 | improved | 54 |
| P-01342 | 23% | S11 | DT-01 | improved | 48 |
| P-01556 | 63% | S14 | GI-04 | improved | 44 |